Tenoretic Dosing and Management
Start with Tenoretic 50 (atenolol 50 mg + chlorthalidone 12.5 mg) once daily, and if blood pressure remains uncontrolled after adequate trial, increase to Tenoretic 100 (atenolol 100 mg + chlorthalidone 25 mg) once daily. 1
Starting Dose and Titration
The FDA-approved dosing for Tenoretic is straightforward:
- Initial dose: Tenoretic 50 (atenolol 50 mg + chlorthalidone 12.5 mg) once daily 1
- Titration: If blood pressure control is inadequate, increase to Tenoretic 100 (atenolol 100 mg + chlorthalidone 25 mg) once daily 1
- Timing: Take once daily in the morning for optimal 24-hour coverage
The combination is particularly effective because chlorthalidone at 12.5-25 mg provides proven cardiovascular outcome benefits 2, 3, while atenolol addresses the reflex tachycardia and fluid retention that can occur with beta-blockers and diuretics respectively 4, 5, 6.
Renal Dose Adjustments
Critical consideration: Atenolol is renally eliminated and requires dose adjustment in advanced kidney disease 1:
- CrCl 15-35 mL/min/1.73m²: Maximum 50 mg atenolol daily (use only Tenoretic 50)
- CrCl <15 mL/min/1.73m²: Maximum 50 mg atenolol every other day
- Normal renal function (CrCl >35 mL/min/1.73m²): No adjustment needed
For chlorthalidone specifically, recent evidence shows it remains effective even in advanced CKD (stage 4, eGFR ~23 mL/min), reducing 24-hour ambulatory BP by 10.5 mmHg more than placebo 7. However, chlorthalidone may precipitate azotemia in severe renal impairment and requires careful monitoring 8.
Monitoring Requirements
Electrolytes and renal function must be checked 2-4 weeks after initiation or dose changes 9:
Initial Monitoring (First 2-4 weeks):
- Basic metabolic panel including potassium, sodium, creatinine
- Blood pressure measurement (ideally 24 hours post-dose to assess trough effect) 2
- Watch for hypokalemia (chlorthalidone effect) - occurs in 8.5% at 25 mg dose 10
- Monitor for hyperkalemia if patient is on ACE inhibitors or ARBs concurrently
Ongoing Monitoring:
- Electrolytes every 3-6 months once stable
- More frequent monitoring (every 1-2 weeks) if CKD present 11
- Serum creatinine - expect small increases (up to 0.3 mg/dL acceptable)
- Uric acid levels - gout is uncommon at chlorthalidone ≤25 mg 2
Important pitfall: Chlorthalidone has a 24-72 hour duration of action 12, 13, meaning electrolyte disturbances can develop gradually. Don't assume normal labs at 1 week mean the patient is safe long-term.
Contraindications
Absolute contraindications:
- Severe renal failure (CrCl <15 mL/min without dialysis adjustment)
- Sinus bradycardia, heart block greater than first degree
- Cardiogenic shock
- Overt cardiac failure (decompensated)
- Anuria or severe electrolyte imbalances
- Asthma or severe COPD (atenolol is non-selective at higher doses)
Relative contraindications requiring caution:
- Diabetes mellitus (beta-blockers mask hypoglycemia symptoms) 8
- Peripheral vascular disease
- History of severe allergic reactions (atenolol may increase reaction severity)
- Concurrent use with other negative chronotropes (diltiazem, verapamil)
Special Populations
Black Patients
Thiazide-type diuretics like chlorthalidone are first-line therapy in black patients with hypertension 3. The combination of beta-blocker plus thiazide is explicitly listed as appropriate therapy 2. Chlorthalidone 12.5-25 mg has superior outcomes compared to ACE inhibitors in this population 3.
Elderly Patients
Multiple studies demonstrate excellent efficacy and tolerability in elderly hypertensives (ages 61-80) with the 50 mg/12.5 mg combination, achieving mean BP reductions of 30/15 mmHg 4. The lower dose combination is preferred to minimize adverse effects while maintaining efficacy.
Heart Failure
Do not use Tenoretic in acute decompensated heart failure 12. Beta-blockers are contraindicated in overt cardiac failure. However, in stable heart failure with hypertension, the components may be used separately with careful titration.
Clinical Pearls
- Bioavailability: The fixed combination has equivalent bioavailability to free combination or individual components 14, 15
- Potassium-sparing effect: The combination may partially offset chlorthalidone-induced hypokalemia compared to chlorthalidone alone 6
- 24-hour coverage: Measure BP just before next dose to ensure adequate trough effect 2
- Add-on therapy: If additional BP lowering needed, add 50% of usual starting dose of another agent to avoid excessive hypotension 1
- Withdrawal: Never stop abruptly - taper to avoid rebound hypertension (especially relevant for atenolol component)